What Happened?
Shares of healthcare services company Chemed Corporation (NYSE: CHE) jumped 8.8% in the afternoon session after the company reported first-quarter 2026 results that topped Wall Street's expectations for both revenue and profit.
The company's revenue for the quarter was $657.5 million, an increase of 1.6% from the previous year, while its adjusted earnings per share came in at $5.65, surpassing analyst estimates by 6.6%. Chemed's adjusted EBITDA of $116.3 million also beat consensus forecasts. Investors were likely encouraged by the company's strong cash generation, as its free cash flow margin expanded to 10.8%, a significant jump from 3% in the same quarter last year. Overall, the market reacted positively to the earnings beat across key metrics.
Is now the time to buy Chemed? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Chemed’s shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was about 2 months ago when the stock dropped 15.6% on the news that the company reported financial results for the fourth quarter of 2025 that missed Wall Street's expectations for both revenue and profit.
Chemed's revenue was essentially flat compared to the prior year at $639.3 million, falling short of analyst forecasts. Adjusted earnings per share came in at $6.42, a 6% decrease from the same period in the previous year and also below what analysts had predicted. The company's profitability also came under pressure, with its operating margin—a measure of efficiency—declining to 15.7% from 17.8% in the same quarter last year, indicating that expenses grew faster than sales.
Adding to investor concerns, Chemed provided a full-year 2026 earnings forecast with a midpoint 6.5% below the existing analyst consensus. The combination of missing current estimates, declining profitability, and issuing cautious guidance prompted the significant drop in the stock price.
Chemed is down 1.4% since the beginning of the year, and at $417.85 per share, it is trading 28.1% below its 52-week high of $581.51 from April 2025. Investors who bought $1,000 worth of Chemed’s shares 5 years ago would now be looking at only $896.65.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
